Murdoch University Research Repository

Welcome to the Murdoch University Research Repository

The Murdoch University Research Repository is an open access digital collection of research
created by Murdoch University staff, researchers and postgraduate students.

Learn more

Trilostane treatment in dogs with pituitary-dependent hyperadreno-corticism

Braddock, J.A., Church, D.B., Robertson, I.D.ORCID: 0000-0002-4255-4752 and Watson, A.D.J. (2003) Trilostane treatment in dogs with pituitary-dependent hyperadreno-corticism. Australian Veterinary Journal, 81 (10). pp. 600-607.

Link to Published Version: http://dx.doi.org/10.1111/j.1751-0813.2003.tb12498...
*Subscription may be required

Abstract

Objective
To evaluate the efficacy of trilostane in treating dogs with pituitary-dependent hyperadrenocorticism.

Design
Prospective clinical trial using client-owned dogs with pituitary-dependent hyperadrenocorticism treated at University Veterinary Centre, Sydney from September 1999 to July 2001.

Procedure
Thirty dogs with pituitary-dependent hyperadrenocorticism treated with trilostane, a competitive inhibitor β-HSD, were monitored at days 10, 30 and 90 then 3-monthly by clinical examination, tetracosactrin stimulation testing, urinary corticoid:creatinine ratio measurement and by client questionnaire.

Results
Twenty-nine of 30 dogs were successfully treated with trilostane (median dose 16.7 mg/kg; range 5.3 to 50 mg/kg, administered once daily); one responded favourably but died of unrelated disease before full control was achieved.

Conclusion
Trilostane administration controlled pituitary-dependent hyperadrenocorticism in these dogs. It was safe, effective and free of side-effects at the doses used. Most dogs were initially quite sensitive to the drug for 10 to 30 days, then required higher doses until a prolonged phase of stable dose requirements occurred. Urinary corticoid:creatinine ratio was useful in assessing duration of drug effect. Some dogs treated for more than 2 years required reduction or temporary cessation of drug because of iatrogenic hypoadrenocorticism.

Item Type: Journal Article
Murdoch Affiliation: School of Veterinary and Biomedical Sciences
Publisher: Wiley-Blackwell
URI: http://researchrepository.murdoch.edu.au/id/eprint/16654
Item Control Page Item Control Page